SCHEMBL3713606

SCHEMBL3713606

C[C@H]1CN(C(=O)Nc2ccccc2)CC[N+]1(C(=O)[O-])C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
TP53 P04637 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 1/20 0.48
RBP4 P02753 1/20 0.46
HTT P42858 1/20 0.45
MAPT P10636 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
GRIN2B Q13224 3/20 0.42
FAAH O00519 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3721450 0.78 TAS1R3 (0.46) TP53SMN1; SMN2HTTMAPTKDM4E
SCHEMBL3713712 0.73 LIMK2 (0.42) NPC1TP53RAB9ASMN1; SMN2TSHR
SCHEMBL1821178 0.70 SMN1; SMN2 (0.54) NPC1RAB9ASMN1; SMN2HTTCYP2C9
SCHEMBL7890248 0.69 POLB (0.66) NPC1TP53RAB9ASMN1; SMN2TSHR
SCHEMBL31596964 0.68 NPC1 (0.55) NPC1TP53RAB9ASMN1; SMN2TSHR
SCHEMBL3714521 0.68 KDM4E (0.55) NPC1TP53RAB9ASMN1; SMN2TSHR
SCHEMBL11833345 0.68 LMNA (0.79) NPC1TP53RAB9ASMN1; SMN2TSHR
SCHEMBL10729724 0.68 KDM4E (0.77) SMN1; SMN2HTTMAPTKDM4EALDH1A1
SCHEMBL2897923 0.68 KDM4E (0.77) SMN1; SMN2HTTMAPTKDM4EALDH1A1
SCHEMBL7888115 0.67 RBP4 (0.52) NPC1TP53RAB9ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010102663-A1 PIPERAZINE DERIVATIVES FOR USE IN THERAPY GLAXO GROUP LIMITED (GB) 2010-09-16 WO disclosed